BPC-157 Wound Healing Protocol — Dosage & Timing Guide
Most people don't fail at healing with BPC-157 because the peptide doesn't work. They fail because they inject at the wrong time relative to tissue damage onset. A 250mcg dose administered 12 hours post-injury delivers different healing kinetics than the same dose given 72 hours later, yet most protocols ignore timing entirely. The peptide's mechanism hinges on growth factor upregulation during the inflammatory phase. Miss that window, and you're treating fibrotic tissue instead of guiding new collagen deposition.
Our team has worked with researchers who've tested this peptide across tendon injuries, gastric ulcers, and surgical incisions. The gap between success and wasted injections comes down to three things most guides never mention: peak plasma concentration timing, injection site proximity to injury, and the reconstitution stability window that determines whether your vial still contains active peptide or degraded fragments.
What is the optimal BPC-157 wound healing protocol dosage timing for tissue repair?
BPC-157 demonstrates peak angiogenic and fibroblast proliferation activity when administered within 24–48 hours of injury at 250–500mcg per day, split into two subcutaneous injections spaced 12 hours apart. Timing matters because the peptide upregulates VEGF (vascular endothelial growth factor) and bFGF (basic fibroblast growth factor) during the inflammatory phase. The 72-hour window when your body decides whether to repair tissue properly or lay down scar tissue. Injecting after this phase closes means you're modulating a process that's already committed to a healing trajectory.
Here's what separates effective BPC-157 protocols from wasted money: the peptide isn't a passive wound healer that works whenever you inject it. It's a signaling molecule that amplifies the body's existing repair cascade. Which means it needs to be present during the inflammatory and proliferative phases, not after collagen remodeling has already started. The rest of this piece covers the exact dosing schedules by injury type, subcutaneous vs. oral timing differences, reconstitution stability timelines that most suppliers won't discuss, and the injection proximity rule that determines whether the peptide reaches target tissue at therapeutic concentration.
The Inflammatory Window — Why First 48 Hours Matter
BPC-157's mechanism centers on growth factor modulation during acute inflammation. When tissue is damaged, your body releases cytokines (IL-6, TNF-alpha) that trigger the inflammatory cascade. This is the phase where macrophages clear debris and growth factors like VEGF signal new blood vessel formation. BPC-157 doesn't create this process from scratch; it amplifies VEGF expression by approximately 3–4× normal levels and accelerates fibroblast migration to the wound site, according to rodent tendon injury models published in the Journal of Orthopaedic Research.
The 24–48 hour window is critical because that's when growth factor receptor density peaks in damaged tissue. Injecting BPC-157 during this phase means the peptide binds to upregulated receptors and magnifies the repair signal. Injecting after 72 hours means you're arriving after the inflammatory phase has already transitioned to proliferation. Growth factors are declining, macrophage activity is winding down, and the tissue has committed to a specific collagen deposition pattern. You can still influence healing at this stage, but the magnitude of effect drops significantly.
Our experience working with injury recovery protocols shows that patients who start BPC-157 within 12–24 hours of a soft tissue injury report faster resolution of swelling and earlier return to pain-free range of motion compared to those who delay until day 4 or 5. The peptide isn't magic. It's timing-dependent biology. If you're treating a chronic issue (tendinopathy that's been present for months), the inflammatory window logic doesn't apply the same way. You're dealing with ongoing low-grade inflammation rather than acute injury, which changes both dosing frequency and duration.
Dosage Ranges and Administration Routes
Clinical research in animal models and human case reports clusters around 250–500mcg per day as the effective dose range for systemic tissue repair. This isn't arbitrary. Studies on gastric ulcer healing in rats used 10mcg/kg body weight, which scales to approximately 250–350mcg for a 70kg human when applying allometric conversion factors. Higher doses (750mcg–1mg) haven't demonstrated proportionally greater healing in published models, suggesting a ceiling effect where receptor saturation limits additional benefit.
Subcutaneous injection is the standard route. Inject as close to the injury site as practical. Within 2–4 inches if targeting a specific tendon or ligament. The peptide has systemic distribution (it reaches tissues throughout the body after injection), but local concentration matters for site-specific repair. A study in the European Journal of Pharmacology found that BPC-157 administered near injured Achilles tendons produced measurably faster collagen organization than distant injection sites, likely due to higher local peptide concentration during the critical 6–8 hour post-injection window.
Oral BPC-157 exists but requires different timing and higher doses. The peptide is a 15-amino-acid sequence that survives gastric acid degradation better than most peptides, but oral bioavailability is still significantly lower than subcutaneous administration. Estimates range from 10–30% depending on formulation. If using oral capsules (typically acetate salt form), dosing is 500mcg–1mg taken on an empty stomach 30 minutes before meals. Timing here matters because food in the stomach dilutes gastric concentration and delays absorption. Oral administration works better for gastrointestinal issues (ulcers, inflammatory bowel conditions) where direct mucosal contact adds value, but subcutaneous remains superior for musculoskeletal injuries.
Injection Timing Strategy — Once Daily vs. Twice Daily
BPC-157 has an estimated half-life of 4–6 hours in systemic circulation based on peptide degradation kinetics (though exact human pharmacokinetic data remains unpublished). This short half-life is why twice-daily dosing outperforms once-daily protocols. You're maintaining more consistent plasma levels throughout the 24-hour cycle rather than spiking high and dropping low.
A twice-daily schedule looks like this: 250mcg injected subcutaneously at 8 AM, then 250mcg at 8 PM. This maintains peptide presence during both daytime activity (when mechanical stress on injured tissue is highest) and overnight repair cycles (when growth hormone peaks and protein synthesis ramps up). Splitting the dose also reduces the risk of injection site irritation. Some users report mild swelling or redness at injection sites with single 500mcg boluses, which resolves when the same total dose is divided.
Once-daily dosing (500mcg in a single morning injection) is acceptable if twice-daily isn't practical, but expect slightly slower subjective improvement. The peptide still works. You're just giving it a narrower therapeutic window each day. For chronic conditions where you're running a 4–6 week protocol, the cumulative difference between once and twice daily may not be perceptible. For acute injuries where every day of faster healing matters, twice daily is the clear choice.
Our team has found that patients who commit to twice-daily dosing during the first two weeks post-injury, then taper to once daily for maintenance, report the best balance of rapid early gains and sustained healing quality. This isn't a published guideline. It's a practical observation from real-world use cases.
BPC-157 Wound Healing Protocol Dosage Timing Comparison
| Protocol Type | Dosage | Frequency | Timing Window | Injection Site | Best Use Case | Professional Assessment ||—|—|—|—|—|—|| Acute Injury (First 48 Hours) | 250mcg | Twice daily (12-hour spacing) | Within 24 hours of injury | Within 2–4 inches of injury | Tendon strains, ligament sprains, muscle tears | Optimal. Captures inflammatory phase when growth factor receptors peak || Delayed Acute (72 Hours – 7 Days) | 250–350mcg | Twice daily | 3–7 days post-injury | Near injury site | Injuries where immediate treatment wasn't possible | Effective but reduced magnitude. Proliferative phase already underway || Chronic Tendinopathy | 250–300mcg | Once daily | Ongoing (4–8 week cycles) | Rotation of sites near affected tissue | Persistent tendon pain, repetitive strain | Lower dose acceptable. Not targeting acute inflammation || Gastrointestinal Repair | 500mcg–1mg | Once daily (oral) | 30 minutes before first meal | Oral capsule | Gastric ulcers, IBD flare-ups, mucosal damage | Oral route preferred for direct mucosal contact || Post-Surgical Healing | 250–500mcg | Twice daily | Starting 12–24 hours post-op | Proximal to incision site (not directly on sutures) | Surgical incisions, joint reconstruction recovery | Accelerates collagen deposition. Avoid injecting into fresh surgical wounds || Prophylactic (Pre-Injury) | Not recommended | N/A | N/A | N/A | N/A | 1/5. No evidence supports pre-injury use; mechanism requires active tissue damage to function |
Key Takeaways
BPC-157 amplifies VEGF and bFGF signaling during the inflammatory phase, making the first 24–48 hours post-injury the critical dosing window for maximum healing acceleration.
Standard dosing is 250–500mcg per day split into two subcutaneous injections spaced 12 hours apart, injected within 2–4 inches of the injury site for localized soft tissue repair.
The peptide has a 4–6 hour half-life, which is why twice-daily dosing maintains more consistent therapeutic plasma levels than once-daily protocols.
Oral BPC-157 requires 500mcg–1mg doses taken 30 minutes before meals on an empty stomach and works better for gastrointestinal issues than musculoskeletal injuries.
Reconstituted BPC-157 in bacteriostatic water remains stable for 28 days when refrigerated at 2–8°C. Temperature excursions above 8°C accelerate peptide degradation.
Chronic tendinopathy protocols run 4–8 weeks at lower once-daily doses because you're modulating ongoing low-grade inflammation, not acute injury.
What If: BPC-157 Dosage and Timing Scenarios
What If I Didn't Start BPC-157 Until Five Days After My Injury?
Inject at the standard 250mcg twice-daily dose for at least three weeks. You've missed the peak inflammatory window, but the peptide still influences collagen remodeling and angiogenesis during the proliferative phase. Tissue repair continues for 2–4 weeks post-injury even if the acute inflammation has resolved. Delayed treatment won't undo scar tissue that's already formed, but it can improve the quality of ongoing collagen deposition and vascular network development. Expect slower subjective improvement compared to immediate post-injury dosing.
What If I Can Only Inject Once Daily Due to My Schedule?
Administer the full 500mcg dose in a single morning injection rather than splitting it. The peptide will still exert healing effects, but plasma levels will peak and trough more dramatically than with twice-daily dosing. This matters less for chronic conditions than acute injuries. If you're treating a months-old tendinopathy, once-daily dosing is entirely acceptable. If treating a fresh injury where rapid healing matters, consider setting a phone alarm for the evening dose rather than skipping it.
What If My Reconstituted BPC-157 Was Left Out of the Fridge Overnight?
Discard it if the vial was at room temperature (20–25°C) for more than 12 hours. Peptides are temperature-sensitive. The amino acid chain begins to denature at temperatures above 8°C, and while short excursions (2–4 hours) are generally recoverable, overnight exposure significantly degrades potency. You can't visually confirm degradation. The solution will still look clear. But injecting degraded peptide delivers inactive fragments, not therapeutic molecules. Reconstitute a fresh vial rather than gambling on compromised potency.
The Unflinching Truth About BPC-157 Timing
Here's the honest answer: most people dose BPC-157 wrong because they treat it like a supplement instead of a signaling molecule. The peptide doesn't 'heal wounds' the way antibiotic ointment fights bacteria. It modulates your body's existing repair machinery, which means timing determines whether you're amplifying a productive process or arriving after the critical decisions have already been made. Inject BPC-157 on day six of a tendon strain and you're influencing collagen alignment in tissue that's already committed to a specific fiber orientation. Inject on day one and you're guiding the entire deposition pattern from the start.
The difference isn't subtle. We've seen identical injuries treated with identical total doses produce markedly different outcomes based solely on when the first injection occurred. The peptide works. But only if you respect the biology it depends on. Inflammation isn't the enemy; mistimed intervention is.
Reconstitution and Storage — The Stability Timeline
BPC-157 typically arrives as lyophilized powder in 5mg vials. Reconstitute with bacteriostatic water (0.9% benzyl alcohol) at a 1:1 ratio. 2mL of bacteriostatic water into a 5mg vial yields a 2.5mg/mL solution, where each 0.1mL (10 units on an insulin syringe) contains 250mcg of peptide. Inject bacteriostatic water slowly down the inside wall of the vial to avoid foaming, which can denature the peptide structure. Swirl gently. Never shake.
Refrigerate immediately at 2–8°C. Reconstituted peptides remain stable for 28 days under these conditions, but potency declines gradually starting around day 21. If you're running a standard protocol (250mcg twice daily from a 5mg vial), you'll use the entire vial in 10 days. Well within the stability window. Longer protocols requiring multiple vials should reconstitute fresh vials rather than mixing all doses upfront.
Lyophilized (unreconstituted) peptide stored at −20°C remains stable for 12–24 months. Room temperature storage of lyophilized powder is acceptable for short periods (up to 30 days) but accelerates degradation. Keep unopened vials refrigerated or frozen until ready to reconstitute. Once mixed with bacteriostatic water, the peptide must stay cold. There's no recovery from temperature-induced denaturation.
At Real Peptides, every batch undergoes exact amino-acid sequencing to confirm structural integrity before shipping. This matters because even single amino acid substitutions can render the peptide inactive. Our small-batch synthesis process guarantees you're injecting the full 15-amino-acid BPC-157 sequence, not truncated fragments or contaminated preparations that lack therapeutic activity.
Injecting degraded peptide isn't just ineffective. It wastes the injury's critical healing window. Store it right, or don't bother injecting it at all.
Frequently Asked Questions
Inject BPC-157 at consistent 12-hour intervals — for example, 8 AM and 8 PM — to maintain stable plasma levels throughout the 24-hour cycle. The peptide has a 4–6 hour half-life, so twice-daily dosing ensures therapeutic concentration during both daytime activity and overnight repair phases when growth hormone and protein synthesis peak. Morning and evening timing also aligns with practical meal schedules if you’re combining subcutaneous BPC-157 with oral dosing protocols.
Start BPC-157 within 24–48 hours of injury to capture the inflammatory phase when growth factor receptors are most active. The peptide upregulates VEGF and fibroblast activity during this window, which determines collagen deposition quality. Delayed treatment (72+ hours post-injury) still provides benefit during the proliferative phase, but the magnitude of healing acceleration decreases because early inflammatory signaling has already committed tissue to a specific repair trajectory.
Yes, but dosing strategy differs from acute protocols. Chronic tendinopathy involves ongoing low-grade inflammation rather than the acute inflammatory phase seen in fresh injuries. Use 250–300mcg once daily for 4–8 week cycles instead of twice-daily acute dosing. The peptide still modulates angiogenesis and collagen remodeling in chronic tissue, but without the amplified growth factor receptor density present in the first 72 hours post-injury, healing timelines extend significantly.
Resume your normal schedule with the next planned dose — do not double-dose to compensate. Missing a single injection won’t derail healing, but frequent missed doses reduce cumulative peptide exposure during critical repair phases. If you’re running a twice-daily protocol and consistently miss evening doses, you’re effectively on a once-daily schedule with suboptimal plasma level consistency. Set reminders to maintain dosing discipline, especially during the first two weeks post-injury when timing matters most.
Inject within 2–4 inches of the injured tissue for localized soft tissue injuries like tendon strains or ligament sprains. The peptide has systemic distribution after subcutaneous injection, but local concentration at the injury site is higher when injected proximally. Research on Achilles tendon injuries showed faster collagen organization with near-site injection compared to distant administration. For systemic issues (gastric ulcers, widespread inflammation), injection site proximity matters less — oral or abdominal subcutaneous dosing works equally well.
Subcutaneous injection delivers superior bioavailability for musculoskeletal injuries — oral absorption is only 10–30% due to gastric enzyme degradation, even though BPC-157 survives stomach acid better than most peptides. Oral dosing (500mcg–1mg before meals) is more effective for gastrointestinal issues where direct mucosal contact adds therapeutic value. For tendon, ligament, or muscle injuries, subcutaneous administration at 250–500mcg per day split into two doses provides faster healing and requires lower total peptide consumption.
Acute injury protocols typically run 3–6 weeks until functional recovery is achieved. Chronic condition protocols run 4–8 week cycles with 2–4 week breaks between cycles to avoid receptor downregulation. There’s no published evidence of toxicity from continuous BPC-157 use, but extended dosing without breaks may reduce receptor sensitivity over time. If healing plateaus before full recovery, take a two-week break then resume at the same dose rather than increasing dosage indefinitely.
BPC-157 acetate is the stable salt form used in most research-grade preparations and is suitable for both subcutaneous and oral administration. Arginine salt is a less common variant that some suppliers claim offers improved oral bioavailability, but peer-reviewed evidence supporting this difference is limited. Both forms contain the same 15-amino-acid sequence and function identically once absorbed. Focus on purity and proper reconstitution rather than salt form — sequence integrity matters more than formulation nuances.
BPC-157 can be used concurrently with NSAIDs (ibuprofen, naproxen), but understand the mechanistic tension: NSAIDs suppress the inflammatory cascade that BPC-157 depends on to upregulate growth factors. If possible, limit NSAID use to the first 48–72 hours for pain management, then taper off as BPC-157 dosing continues. The peptide’s healing mechanism works with inflammation, not against it — blocking COX enzymes may blunt some of BPC-157’s angiogenic effects during the critical early repair window.
You can’t visually confirm potency — degraded peptide looks identical to fresh solution. Reconstituted BPC-157 in bacteriostatic water remains stable for 28 days when refrigerated at 2–8°C, with gradual potency decline starting around day 21. If healing progress stalls unexpectedly mid-protocol and your vial is older than three weeks, reconstitute a fresh vial. Temperature excursions above 8°C (even brief) accelerate degradation — if your vial was left at room temperature for more than 4 hours, discard and start fresh rather than injecting compromised peptide.